Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 5;110(4):656–662. doi: 10.4269/ajtmh.23-0197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024, The author(s)

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Figure 2. — (A) Status of parasite load in patients with post-kala-azar dermal leishmaniasis (PKDL). (i) Scatter plots showing the parasite load in PKDL patients with polymorphic (■; n = 85) or macular (▲; n = 72) lesions as described in Materials and Methods. Representative images of PKDL patients with polymorphic (ii) or macular (iii) lesions. (B) Effect of miltefosine on the parasite load of patients with PKDL. (i) Scatter plots indicating parasite load at disease presentation (●; n = 157) at the end of 12 weeks treatment with miltefosine (■; n = 39) and at 6 months posttreatment (▲; n = 65). Representative images of PKDL patients with persisting polymorphic (ii and iii) or macular (iv) lesions after 2 years and after 6 months, respectively.